Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Non-Current Deffered Revenue (2019 - 2025)

Vivos Therapeutics has reported Non-Current Deffered Revenue over the past 7 years, most recently at $1000.0 for Q3 2025.

  • Quarterly Non-Current Deffered Revenue fell 99.44% to $1000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $1000.0 through Sep 2025, down 99.44% year-over-year, with the annual reading at $97000.0 for FY2024, 66.44% down from the prior year.
  • Non-Current Deffered Revenue was $1000.0 for Q3 2025 at Vivos Therapeutics, down from $5000.0 in the prior quarter.
  • Over five years, Non-Current Deffered Revenue peaked at $533000.0 in Q1 2024 and troughed at $1000.0 in Q3 2025.
  • The 5-year median for Non-Current Deffered Revenue is $250000.0 (2023), against an average of $236235.3.
  • Year-over-year, Non-Current Deffered Revenue surged 158.04% in 2023 and then tumbled 99.44% in 2025.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $343000.0 in 2021, then crashed by 67.35% to $112000.0 in 2022, then surged by 158.04% to $289000.0 in 2023, then plummeted by 66.44% to $97000.0 in 2024, then tumbled by 98.97% to $1000.0 in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Non-Current Deffered Revenue are $1000.0 (Q3 2025), $5000.0 (Q2 2025), and $22000.0 (Q1 2025).